Genmab — Juni 2020
-
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Genmab to $40 from $34 and keeps a Buy rating on the shares. The analyst views AbbVie as a "solid partner" for Genmab alongside Janssen
The Fly | LANDINGPAGENEWS.PHP
Real-time market news, financial data, stock research, and portfolio tools from The Fly.
(thefly.com)
-
GENMAB A/S GMAB.O: SUNTRUST ROBINSON RAISES TARGET PRICE TO $39 FROM $36 - Reuters News
-
Jo UBS og Citi har 2500
-
Abbvie at GS conference from minute 29 https://kvgo.com/GSHC/AbbVie-june-2020
-
thanks E L
-
and Seattle Genetics from minute 13:50 for TV
https://kvgo.com/GSHC/seattle-genetics-june-2020 -
Its a full time job for you to keep up updated E L
-
keep us updated
-
Nightmare scenario, but in some years you will probably follow the presentations from at least 10 companies who have in licensed products from Genmab
-
Join Genmab at the virtual edition of EHA Annual Congress. Visit our booth to get latest information about our presentations, antibody technology platforms and product pipeline.
http://ow.ly/oOod50A4BFT -
BioNtech presentation from early June pdf https://investors.biontech.de/static-files/198e9458-6be7-4064-be9f-5cc1801a6ca9
-
New Genmab/Abbvie tie-up rings old bells https://www.evaluate.com/vantage/articles/news/deals/new-genmababbvie-tie-rings-old-bells
-
NBI -4,10%
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind